Hemgenix® is a gene therapy product for the treatment of adults with severe and moderately severe haemophilia B, who have not developed inhibitors against factor IX. Cross-border consultations resulted in a scientific and budget impact analysis report, approved in both countries where the company submitted the dossier. For Hemgenix®, the pharmacotherapeutic and budgetary assessment were performed by RIZIV-INAMI (Brussels) and the National Health Care Institute (Amsterdam).
The full report can be consulted on the public website of Zorginstituut Nederland.
Last update: 1 August 2024